Anixa Biosciences is trading at $3.50 (+5.42%) following sustained momentum from its Australian patent acceptance for breast cancer vaccine technology.
- The company recently received a notice of allowance for an Australian patent, which has served as the primary catalyst for recent buying interest.
- Shares are showing significant strength in after-hours trading, outperforming a broader biotech market that has remained mixed to weak.